ArticleFrontiers in oncology2025
Primary non-Hodgkin lymphoma in the muscle of left lower extremity: a case report and literature review.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary non-Hodgkin lymphoma (NHL) of the left lower extremity muscle is a rare extra-nodal lymphoma, accounting for less than 1% of all extra-nodal NHL cases. We report a rare case of intramuscular NHL of the left lower extremity and discuss its clinical features, diagnostic challenges, and treatment strategies with reference to the literature. The patient, an adult man, was treated for sudden swelling and pain in the left lower limb. Ultrasound examination revealed hypoechoic myometrium (hematoma considered), and ultrasound-guided puncture biopsy confirmed "primary CD5+ diffuse large B-cell lymphoma (leg type)". The patient received six cycles of chemotherapy, and his symptoms were significantly relieved, but an early local recurrence occurred. The clinical manifestations and imaging features of primary NHL in skeletal muscle lacked specificity, and the diagnosis depended on pathology and molecular analysis. Its pathogenesis may be related to direct invasion, hematogenous metastasis, or primary muscle lesions. CD5+ diffuse large B-cell lymphoma (DLBCL) is aggressive, and Rituximab-Cyclophosphamide Hydroxydaunorubicin Vincristine Prednisone (R-CHOP) combined with radiotherapy is recommended, but prognosis is affected by age, Lactate Dehydrogenase (LDH) levels, and molecular characteristics such as TP53 mutations. Primary non-Hodgkin lymphoma in the muscle of the left lower limb is very rare. It is difficult to diagnose it by imaging examination alone. It needs to be considered comprehensively by combining various examination methods. Pathology is the gold standard for diagnosis. Radiotherapy and chemotherapy are the first choice for treatment. It is very important to formulate a reasonable treatment plan according to the results of pathology and molecular analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.